On September 25, Moderna, Inc. rose 3.58% overnight, trading at $203.35 per share with turnover of $6.7647 million, breaking through the $200 level to mark a fresh high.
On the news front, the rally was driven by continued momentum surrounding the company's personalized mRNA cancer vaccine intismeran autogene. Moderna announced that three research abstracts related to the vaccine have been accepted by the European Society for Medical Oncology annual meeting. Most notably, the complete Phase 3 INTerpath-001 trial data on melanoma will be formally presented on October 24 in the presidential symposium — the highest-visibility slot at the conference. Two additional abstracts will disclose clinical data for the vaccine in pancreatic cancer and early-stage non-small cell lung cancer.
Adding to the bullish backdrop, a $9.18 million deep in-the-money call option block trade recently appeared in the options market, targeting November expiration at a $160 strike, signaling concentrated institutional conviction in further upside. Multiple analysts have raised price targets in recent weeks following the Phase 3 clinical success announced in August, with Argus Research upgrading the stock to Buy with a $180 target.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments